Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 7/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869458 | 1.00 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL8867641 | 0.85 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL18425051 | 0.85 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL30485002 | 0.85 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL15123090 | 0.85 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL15123091 | 0.85 | KYNU (0.57) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL24130582 | 0.84 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL6498057 | 0.84 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL24130581 | 0.84 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL3249670 | 0.84 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | KYNU 643/4885ALDH1A1 1305/4885ALOX15 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.